A case of inclusion body myositis responsive to prednisolone therapy.
Inclusion body myositis, although rare, is the commonest cause of myopathy in patients aged over 50 years. The suggested pathogenesis remains uncertain and its prognosis remains poor. There have been select case reports of its association with an inflammatory etiology and it is postulated that this group of patients respond better to immunosuppressive therapy. We therefore report a rare case of inclusion body myositis that responded well to immunosuppressive therapy. We also report the possibility of its association with infliximab therapy.
Kalla
Rahul
R
Department of Rheumatology, James Cook University Hospitals, Marton Road, Middlesbrough, TS4 3BW, UK. kallarahul@gmail.com
Soumakiyan
Majella
M
Tuck
Stephen
S
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D018979:Myositis, Inclusion Body / Q000139:chemically induced / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D011239:Prednisolone; D000069285:Infliximab